Buyout rumors are once again circulating about AUPH stock on January 21, 2022. The rumors appear to be circulating from a STAT article published on January 13, 2022.
Biogen working with Goldman to explore possible acquisitions, STAT says
On January 13, 2022, Biogen (BIIB), whose stock price is down nearly 50% since June when its controversial Alzheimer’s treatment Aduhelm was granted FDA approval, has been working with Goldman Sachs (GS) to find potential buyout targets and has a shopping list from the bank of potential acquisitions, STAT’s Damian Garde and Adam Feuerstein reported, citing a person familiar with the matter. Goldman provided Biogen with a list of smaller biotech companies that might fit with the company’s focus on neuroscience, including Biohaven Pharmaceutical (BHVN), Aurinia Pharmaceuticals (AUPH) and Amylyx (AMLX) and “the company’s risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive,” the biotech reporters said. Source: https://www.statnews.com/2022/01/13/with-its-alzheimers-drug-in-turmoil-biogen-eyes-a-list-of-potential-acquisitions/
Aurinia Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
On December 10, 2021, Oppenheimer analyst Justin Kim upgraded Aurinia Pharmaceuticals to Outperform from Perform with a price target of $31, down from $33. The upgrade is primarily based on valuation and an unchanged view of the commercial outlook for Lupkynis, though it coincides with a positive update from the recently completed AURORA 2 study, Kim tells investors in a research note. Current share levels do not appreciate the fundamental value of Lupkynis’ commercial potential, the analyst adds.
Aurinia Pharmaceuticals reports ‘positive’ results from AURORA 2 study
On December 9, 2021, Aurinia Pharmaceuticals announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS for the treatment of adults with active lupus nephritis, a serious complication in patients with systemic lupus erythematosus. In combination with background immunosuppressive therapy, LUPKYNIS is the first and only FDA-approved medicine with three years of pivotal trial results, including long-term safety data, within LN. Highlights of topline results from AURORA 2: In the 116 subjects in the voclosporin-treated group who enrolled in AURORA 2, mean estimated glomerular filtration rate was stable over 36 months. Compared to the active control group, the voclosporin-treated group showed an increase from baseline eGFR at the end of the studies of +2.7 mL/min. The drug was well tolerated with no unexpected safety signals observed. There were comparable serious adverse events rates in both arms. The active control group had a higher percentage of withdrawals compared to the voclosporin-treated group, 15.0% vs. 12.9% respectively. There were four deaths during AURORA 2 in the active control group, none in the voclosporin-treated group. The mean Urine Protein Creatinine Ratio was lower in the voclosporin-treated groups at all time points during the three years.
📺 Aurinia Pharmaceuticals CEO: Speculative Savior? | Mad Money | CNBC
[embedyt] https://www.youtube.com/watch?v=or5pLOSAHik[/embedyt]📉 AUPH Stock Technical Analysis
The short-term trend is negative, as is the long-term trend. AUPH is part of the Biotechnology industry. There are 635 other stocks in this industry. AUPH outperforms 87% of them. AUPH is currently trading in the middle of its 52-week range. This is in line with the S&P500 Index, which is also trading in the middle of its range.
There is a resistance zone ranging from 17.78 to 18.02. This zone is formed by a combination of multiple trend lines in multiple time frames. There is also a resistance zone ranging from 18.81 to 18.96. This zone is formed by a combination of multiple trend lines and important moving averages in the daily time frame. Finally, there is a resistance zone ranging from 19.71 to 19.91. This zone is formed by a combination of multiple trend lines in multiple time frames.
The technical rating of AUPH is bad and it also does not present a quality setup at the moment. AUPH stock has a Setup Rating of 3 out of 10. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when AUPH stock consolidates and has a Setup Rating of 8 or higher.
